Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey-Reference-Cited by-同舟云学术

Real-world management of chronic myeloid leukemia in South Korea: the TARGET survey

Published:2021-03-31 Issue:1 Volume:56 Page:31-37
ISSN:2287-979X
Container-title:BLOOD RESEARCH
language:en
Short-container-title:Blood Res

Author:

Uhm Jieun¹,Kim Kyoung Ha²,Lee Hyewon³,Kim Hawk⁴,Cassandra Slader⁵,Joo Inkyung⁶,Jung Chul Won⁷

Affiliation:

1. Division of Hematology Oncology, Department of Internal Medicine, Hanyang University Hospital, Hanyang University College of Medicine, Korea

2. Division of Hematology Oncology, Department of Internal Medicine, Soonchunhyang University College of Medicine, Seoul, Korea

3. Division of Tumor Immunology and Center for Hematologic Malignancies, Research Institute and Hospital, National Cancer Center, Goyang, Korea

4. Division of Hematology, Gachon University Gil Medical Center, Gachon University College of Medicine, Incheon, Korea

5. Novartis, Ltd., Seoul, Korea

6. Novartis Korea, Seoul, Korea

7. Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea

Funder

Novartis Korea

Publisher

The Korean Society of Hematology

Subject

Hematology

Link

https://pdf.medrang.co.kr/BR/2021/056/BR2056-01-07.pdf

Reference9 articles.

1. Chronic Myelogenous Leukemia, Version 1.2015

2. Chronic myeloid leukaemia: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

3. The chronic myeloid leukemia stem cell: stemming the tide of persistence

4. Nationwide statistical analysis of myeloid malignancies in Korea: incidence and survival rate from 1999 to 2012

5. National Comprehensive Cancer Network. NCCN Practice Guidelines in Oncology: chronic myeloid leukemia. Version 4. Plymouth Meeting, PA: National Comprehensive Cancer Network, 2018 (Accessed March 29, 2018, at https://www.nccn.org/professionals/physician_gls/pdf/cml.pdf).

Cited by 2 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Treatment after failure of frontline therapy of chronic myeloid leukemia in chronic phase including allogeneic hematopoietic stem cell transplantation;Blood Research;2023-04-30

2. Asciminib: the first-in-class allosteric inhibitor of BCR::ABL1 kinase;Blood Research;2023-03-09